{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T15:15:14Z","timestamp":1794323714831,"version":"4.9.0"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Startup Fund for Advanced Talents of Putian University","award":["2026022"],"award-info":[{"award-number":["2026022"]}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2026J0011082"],"award-info":[{"award-number":["2026J0011082"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"DOI":"10.1186\/s40478-026-02327-6","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T09:58:37Z","timestamp":1779443917000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CD155 and its receptors in glioma: prospects for emerging immune checkpoint inhibitors"],"prefix":"10.1186","volume":"14","author":[{"given":"Mingyao","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youchen","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"2327_CR1","first-page":"299","volume":"70","author":"AC Tan","year":"2020","unstructured":"Tan AC, Ashley DM, Lopez GY, Malinzak M, Friedman HS, Khasraw M (2020) Management of glioblastoma: state of the art and future directions. CA Cancer J Clin 70:299\u2013312","journal-title":"CA Cancer J Clin"},{"key":"2327_CR2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231\u20131251","journal-title":"Neuro Oncol"},{"key":"2327_CR3","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","volume":"31","author":"DF Quail","year":"2017","unstructured":"Quail DF, Joyce JA (2017) The microenvironmental landscape of brain tumors. Cancer Cell 31:326\u2013341","journal-title":"Cancer Cell"},{"key":"2327_CR4","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.trecan.2015.10.009","volume":"1","author":"D Hambardzumyan","year":"2015","unstructured":"Hambardzumyan D and Bergers G (2015) Glioblastoma: defining tumor niches. Trends Cancer 1 252\u2013265","journal-title":"Trends Cancer"},{"key":"2327_CR5","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bahr O, Phuphanich S, Sepulveda JM, De Souza P, Sahebjam S, Carleton M, Tatsuoka K, Taitt C, Zwirtes R, Sampson J, Weller M (2020) Effect of Nivolumab vs Bevacizumab in Patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol 6:1003\u20131010","journal-title":"JAMA Oncol"},{"key":"2327_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11864-019-0619-4","volume":"20","author":"T McGranahan","year":"2019","unstructured":"McGranahan T, Therkelsen KE, Ahmad S, Nagpal S (2019) Current state of immunotherapy for treatment of glioblastoma. Curr Treat Options Oncol 20:24","journal-title":"Curr Treat Options Oncol"},{"key":"2327_CR7","doi-asserted-by":"publisher","first-page":"594","DOI":"10.2174\/1566524021666210910112906","volume":"22","author":"SS Nandi","year":"2022","unstructured":"Nandi SS, Gohil T, Sawant SA, Lambe UP, Ghosh S, Jana S (2022) CD155: A key receptor playing diversified roles. Curr Mol Med 22:594\u2013607","journal-title":"Curr Mol Med"},{"key":"2327_CR8","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.2174\/0929867330666230324152532","volume":"31","author":"Y Mu","year":"2024","unstructured":"Mu Y, Guan X (2024) CD155-TIGIT axis as a therapeutic target for cancer immunotherapy. Curr Med Chem 31:1634\u20131645","journal-title":"Curr Med Chem"},{"key":"2327_CR9","doi-asserted-by":"publisher","first-page":"111896","DOI":"10.1016\/j.intimp.2024.111896","volume":"131","author":"JW Wu","year":"2024","unstructured":"Wu JW, Liu Y, Dai XJ, Liu HM, Zheng YC, Liu HM (2024) CD155 as an emerging target in tumor immunotherapy. Int Immunopharmacol 131:111896","journal-title":"Int Immunopharmacol"},{"key":"2327_CR10","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s00277-025-06304-2","volume":"104","author":"F Meng","year":"2025","unstructured":"Meng F, Xiang M, Liu Y, Zeng D (2025) TIGIT\/PVR axis regulates anti-tumor immunity in hematologic malignancies. Ann Hematol 104:1415\u20131426","journal-title":"Ann Hematol"},{"key":"2327_CR11","doi-asserted-by":"publisher","first-page":"6375","DOI":"10.1158\/0008-5472.CAN-17-0381","volume":"77","author":"W He","year":"2017","unstructured":"He W, Zhang H, Han F, Chen X, Lin R, Wang W, Qiu H, Zhuang Z, Liao Q, Zhang W, Cai Q, Cui Y, Jiang W, Wang H, Ke Z (2017) CD155T\/TIGIT Signaling regulates CD8(+) T-cell Metabolism and promotes tumor progression in human gastric cancer. Cancer Res 77:6375\u20136388","journal-title":"Cancer Res"},{"key":"2327_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12964-023-01455-z","volume":"22","author":"M Huang","year":"2024","unstructured":"Huang M, Yu X, Wang Q, Jiang Z, Li X, Chen W, Song C (2024) The immune checkpoint TIGIT\/CD155 promotes the exhaustion of CD8\u2009+\u2009T cells in TNBC through glucose metabolic reprogramming mediated by PI3K\/AKT\/mTOR signaling. Cell Commun Signal 22:35","journal-title":"Cell Commun Signal"},{"key":"2327_CR13","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.immuni.2014.02.012","volume":"40","author":"N Joller","year":"2014","unstructured":"Joller N, Lozano E, Burkett PR, Patel B, Xiao S, Zhu C, Xia J, Tan TG, Sefik E, Yajnik V, Sharpe AH, Quintana FJ, Mathis D, Benoist C, Hafler DA, Kuchroo VK (2014) Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity 40:569\u2013581","journal-title":"Immunity"},{"key":"2327_CR14","doi-asserted-by":"publisher","first-page":"10312","DOI":"10.1038\/s41467-024-54569-4","volume":"15","author":"R Barakat","year":"2024","unstructured":"Barakat R, Chatterjee J, Mu R, Qi X, Gu X, Smirnov I, Cobb O, Gao K, Barnes A, Kipnis J, Gutmann DH (2024) Human single cell RNA-sequencing reveals a targetable CD8(+) exhausted T cell population that maintains mouse low-grade glioma growth. Nat Commun 15:10312","journal-title":"Nat Commun"},{"key":"2327_CR15","doi-asserted-by":"publisher","first-page":"e1466769","DOI":"10.1080\/2162402X.2018.1466769","volume":"7","author":"AL Hung","year":"2018","unstructured":"Hung AL, Maxwell R, Theodros D, Belcaid Z, Mathios D, Luksik AS, Kim E, Wu A, Xia Y, Garzon-Muvdi T, Jackson C, Ye X, Tyler B, Selby M, Korman A, Barnhart B, Park SM, Youn JI, Chowdhury T, Park CK, Brem H, Pardoll DM, Lim M (2018) TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. Oncoimmunology 7:e1466769","journal-title":"Oncoimmunology"},{"key":"2327_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12915-025-02132-y","volume":"23","author":"X Zhang","year":"2025","unstructured":"Zhang X, Zhang L, Li B, Wang Q, Chen P, Shi R, Zhou X, Niu X, Zhai W, Wu Y, Shen W, Zhou X, Zhao W (2025) Identification of Epinastine as CD96\/PVR inhibitor for cancer immunotherapy. BMC Biol 23:27","journal-title":"BMC Biol"},{"key":"2327_CR17","doi-asserted-by":"publisher","first-page":"1441730","DOI":"10.3389\/fimmu.2024.1441730","volume":"15","author":"K Murakami","year":"2024","unstructured":"Murakami K, Ganguly S (2024) The Nectin family ligands, PVRL2 and PVR, in cancer immunology and immunotherapy. Front Immunol 15:1441730","journal-title":"Front Immunol"},{"key":"2327_CR18","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.immuni.2020.09.010","volume":"53","author":"M Braun","year":"2020","unstructured":"Braun M, Aguilera AR, Sundarrajan A, Corvino D, Stannard K, Krumeich S, Das I, Lima LG, Meza Guzman LG, Li K, Li R, Salim N, Jorge MV, Ham S, Kelly G, Vari F, Lepletier A, Raghavendra A, Pearson S, Madore J, Jacquelin S, Effern M, Quine B, Koufariotis LT, Casey M, Nakamura K, Seo EY, Holzel M, Geyer M, Kristiansen G, Taheri T, Ahern E, Hughes BGM, Wilmott JS, Long GV, Scolyer RA, Batstone MD, Landsberg J, Dietrich D, Pop OT, Flatz L, Dougall WC, Veillette A, Nicholson SE, Moller A, Johnston RJ, Martinet L, Smyth MJ, Bald T (2020) CD155 on Tumor Cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8(+) T cells. Immunity 53:805\u2013823e815","journal-title":"Immunity"},{"key":"2327_CR19","doi-asserted-by":"publisher","first-page":"e000957","DOI":"10.1136\/jitc-2020-000957","volume":"8","author":"JM Chauvin","year":"2020","unstructured":"Chauvin JM, Zarour HM (2020) TIGIT in cancer immunotherapy. J Immunother Cancer 8:e000957","journal-title":"J Immunother Cancer"},{"key":"2327_CR20","doi-asserted-by":"publisher","first-page":"699895","DOI":"10.3389\/fimmu.2021.699895","volume":"12","author":"Z Ge","year":"2021","unstructured":"Ge Z, Peppelenbosch MP, Sprengers D, Kwekkeboom J (2021) TIGIT, the next step towards successful combination immune checkpoint therapy in cancer. Front Immunol 12:699895","journal-title":"Front Immunol"},{"key":"2327_CR21","doi-asserted-by":"publisher","first-page":"216381","DOI":"10.1016\/j.canlet.2023.216381","volume":"573","author":"R Zhou","year":"2023","unstructured":"Zhou R, Chen S, Wu Q, Liu L, Wang Y, Mo Y, Zeng Z, Zu X, Xiong W, Wang F (2023) CD155 and its receptors in cancer immune escape and immunotherapy. Cancer Lett 573:216381","journal-title":"Cancer Lett"},{"key":"2327_CR22","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1002\/j.1460-2075.1990.tb07520.x","volume":"9","author":"S Koike","year":"1990","unstructured":"Koike S, Horie H, Ise I, Okitsu A, Yoshida M, Iizuka N, Takeuchi K, Takegami T, Nomoto A (1990) The poliovirus receptor protein is produced both as membrane-bound and secreted forms. EMBO J 9:3217\u20133224","journal-title":"EMBO J"},{"key":"2327_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virusres.2017.09.001","volume":"242","author":"JR Bowers","year":"2017","unstructured":"Bowers JR, Readler JM, Sharma P, Excoffon K (2017) Poliovirus Receptor: More than a simple viral receptor. Virus Res 242:1\u20136","journal-title":"Virus Res"},{"key":"2327_CR24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0006-291X(03)01560-2","volume":"309","author":"B Baury","year":"2003","unstructured":"Baury B, Masson D, McDermott BM Jr., Jarry A, Blottiere HM, Blanchardie P, Laboisse CL, Lustenberger P, Racaniello VR, Denis MG (2003) Identification of secreted CD155 isoforms. Biochem Biophys Res Commun 309:175\u2013182","journal-title":"Biochem Biophys Res Commun"},{"key":"2327_CR25","doi-asserted-by":"publisher","first-page":"e200143","DOI":"10.1212\/NXI.0000000000200143","volume":"10","author":"W Li","year":"2023","unstructured":"Li W, Deng C, Yang H, Tian X, Chen L, Liu Q, Gao C, Lu X, Wang G, Peng Q (2023) Upregulation of the CD155-CD226 axis is associated with muscle inflammation and disease severity in idiopathic inflammatory myopathies. Neurol Neuroimmunol Neuroinflamm 10:e200143","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2327_CR26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.semcancer.2019.11.013","volume":"65","author":"JS O\u2019Donnell","year":"2020","unstructured":"O\u2019Donnell JS, Madore J, Li XY, Smyth MJ (2020) Tumor intrinsic and extrinsic immune functions of CD155. Semin Cancer Biol 65:189\u2013196","journal-title":"Semin Cancer Biol"},{"key":"2327_CR27","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1158\/2326-6066.CIR-23-0752","volume":"12","author":"Z Alteber","year":"2024","unstructured":"Alteber Z, Cojocaru G, Granit RZ, Barbiro I, Wool A, Frenkel M, Novik A, Shuchami A, Liang Y, Carmi VD, Sabath N, Foreman R, Petrenko N, He J, Kliger Y, Levy-Barda A, Eitan R, Raban O, Sadot E, Sulimani O, Nathan AA, Adewoye H, Ferre P, Levine Z, Ophir E (2024) PVRIG is expressed on stem-like T cells in dendritic cell-rich niches in tumors and its blockade may induce immune infiltration in non-inflamed tumors. Cancer Immunol Res 12:876\u2013890","journal-title":"Cancer Immunol Res"},{"key":"2327_CR28","doi-asserted-by":"publisher","first-page":"110682","DOI":"10.1016\/j.clim.2026.110682","volume":"284","author":"C Zhang","year":"2026","unstructured":"Zhang C, Pan Z, Ma X, Zhao D, Yan X, Jia Y, Ren K, Ding J, Wang Y, Li H, Guo J (2026) Polymorphonuclear myeloid-derived suppressor cells inhibit natural killer cell function in neuromyelitis optica spectrum disorder via the CD155-TIGIT axis. Clin Immunol 284:110682","journal-title":"Clin Immunol"},{"key":"2327_CR29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/stcltm\/szaf036","volume":"14","author":"K Ozaki","year":"2025","unstructured":"Ozaki K, Aoki T, Kobayashi M, Takami M, Kobayashi M, Ito T, Ogawa K, Tanaka H, Nishii K, Nishimura K, Motoyoshi K, Kojima I, Katsumi D, Shimizu D, Wang H, Kimura MY, Hirahara K, Koseki H, Higuchi Y, Motohashi S (2025) Anti-tumor effect of intratumoral administration of induced pluripotent stem cell-derived NKT cells on glioblastoma through CD155\/DNAM-1 interaction. Stem Cells Transl Med 14:szaf036","journal-title":"Stem Cells Transl Med"},{"key":"2327_CR30","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s00262-025-04128-7","volume":"74","author":"EC Sundstrom","year":"2025","unstructured":"Sundstrom EC, Huang X, Wiemer AJ (2025) Anti-TIGIT therapies: a review of preclinical and clinical efficacy and mechanisms. Cancer Immunol Immunother 74:272","journal-title":"Cancer Immunol Immunother"},{"key":"2327_CR31","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","volume":"10","author":"X Yu","year":"2009","unstructured":"Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, Tom I, Ivelja S, Refino CJ, Clark H, Eaton D, Grogan JL (2009) The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol 10:48\u201357","journal-title":"Nat Immunol"},{"key":"2327_CR32","doi-asserted-by":"publisher","first-page":"e70212","DOI":"10.1111\/cts.70212","volume":"18","author":"G Srikanth","year":"2025","unstructured":"Srikanth G, Beda DP, Dwivedi AR, Duddukuri NK, Nanduri S, Patel J (2025) Promising new anti-TIGIT agents: stealthy allies in cancer immunotherapy. Clin Transl Sci 18:e70212","journal-title":"Clin Transl Sci"},{"key":"2327_CR33","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3390\/biom15071007","volume":"15","author":"K Liu","year":"2025","unstructured":"Liu K, Liu Y, Xiong H, Ning Z (2025) The immune regulatory functions of CD226 and its implications in immune-mediated diseases. Biomolecules 15:1007","journal-title":"Biomolecules"},{"key":"2327_CR34","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1038\/s12276-024-01317-9","volume":"56","author":"Y Jo","year":"2024","unstructured":"Jo Y, Sim HI, Yun B, Park Y, Jin HS (2024) Revisiting T-cell adhesion molecules as potential targets for cancer immunotherapy: CD226 and CD2. Exp Mol Med 56:2113\u20132126","journal-title":"Exp Mol Med"},{"key":"2327_CR35","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41423-023-00978-2","volume":"20","author":"J Viot","year":"2023","unstructured":"Viot J, Abdeljaoued S, Vienot A, Seffar E, Spehner L, Bouard A, Asgarov K, Pallandre JR, Renaude E, Klajer E, Molimard C, Monnien F, Bibeau F, Turco C, Heyd B, Peixoto P, Hervouet E, Loyon R, Doussot A, Borg C, Kroemer M (2023) CD8(+) CD226(high) T cells in liver metastases dictate the prognosis of colorectal cancer patients treated with chemotherapy and radical surgery. Cell Mol Immunol 20:365\u2013378","journal-title":"Cell Mol Immunol"},{"key":"2327_CR36","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1097\/MEG.0000000000002916","volume":"37","author":"J Chai","year":"2025","unstructured":"Chai J, Li L, Wu Q, Zhang S (2025) CD96: immunoregulation and its role and prospect in immunotherapy of primary hepatocellular carcinoma. Eur J Gastroenterol Hepatol 37:534\u2013539","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2327_CR37","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3390\/ijms24021303","volume":"24","author":"S Feng","year":"2023","unstructured":"Feng S, Isayev O, Werner J, Bazhin AV (2023) CD96 as a potential immune regulator in cancers. Int J Mol Sci 24:1303","journal-title":"Int J Mol Sci"},{"key":"2327_CR38","doi-asserted-by":"publisher","first-page":"e158444","DOI":"10.1172\/jci.insight.158444","volume":"7","author":"A Rogel","year":"2022","unstructured":"Rogel A, Ibrahim FM, Thirdborough SM, Renart-Depontieu F, Birts CN, Buchan SL, Preville X, King EV, Al-Shamkhani A (2022) Fcgamma receptor-mediated cross-linking codefines the immunostimulatory activity of anti-human CD96 antibodies. JCI Insight 7:e158444","journal-title":"JCI Insight"},{"key":"2327_CR39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.5483\/BMBRep.2021.54.1.229","volume":"54","author":"HS Jin","year":"2021","unstructured":"Jin HS, Park Y (2021) Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy. BMB Rep 54:2\u201311","journal-title":"BMB Rep"},{"key":"2327_CR40","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41419-025-07984-4","volume":"16","author":"H Cui","year":"2025","unstructured":"Cui H, Hamad M, Elkord E (2025) TIGIT in cancer: from mechanism of action to promising immunotherapeutic strategies. Cell Death Dis 16:664","journal-title":"Cell Death Dis"},{"key":"2327_CR41","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/cei.13407","volume":"200","author":"H Harjunpaa","year":"2020","unstructured":"Harjunpaa H, Guillerey C (2020) TIGIT as an emerging immune checkpoint. Clin Exp Immunol 200:108\u2013119","journal-title":"Clin Exp Immunol"},{"key":"2327_CR42","doi-asserted-by":"publisher","first-page":"e712","DOI":"10.1212\/NXI.0000000000000712","volume":"7","author":"LE Lucca","year":"2020","unstructured":"Lucca LE, Lerner BA, Park C, DeBartolo D, Harnett B, Kumar VP, Ponath G, Raddassi K, Huttner A, Hafler DA, Pitt D (2020) Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS. Neurol Neuroimmunol Neuroinflamm 7:e712","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2327_CR43","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1038\/s41467-024-46343-3","volume":"15","author":"KB Lupo","year":"2024","unstructured":"Lupo KB, Yao X, Borde S, Wang J, Torregrosa-Allen S, Elzey BD, Utturkar S, Lanman NA, McIntosh M, Matosevic S (2024) synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy. Nat Commun 15:1909","journal-title":"Nat Commun"},{"key":"2327_CR44","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12967-022-03480-x","volume":"20","author":"L Liu","year":"2022","unstructured":"Liu L, Wang A, Liu X, Han S, Sun Y, Zhang J, Guo L, Zhang Y (2022) Blocking TIGIT\/CD155 signalling reverses CD8(+) T cell exhaustion and enhances the antitumor activity in cervical cancer. J Transl Med 20:280","journal-title":"J Transl Med"},{"key":"2327_CR45","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.4110\/in.2023.23.e9","volume":"23","author":"AM Amitrano","year":"2023","unstructured":"Amitrano AM, Kim M (2023) Metabolic challenges in anticancer CD8 T cell functions. Immune Netw 23:e9","journal-title":"Immune Netw"},{"key":"2327_CR46","doi-asserted-by":"publisher","first-page":"1060112","DOI":"10.3389\/fonc.2023.1060112","volume":"13","author":"N Jantz-Naeem","year":"2023","unstructured":"Jantz-Naeem N, Bottcher-Loschinski R, Borucki K, Mitchell-Flack M, Bottcher M, Schraven B, Mougiakakos D, Kahlfuss S (2023) TIGIT signaling and its influence on T cell metabolism and immune cell function in the tumor microenvironment. Front Oncol 13:1060112","journal-title":"Front Oncol"},{"key":"2327_CR47","doi-asserted-by":"publisher","first-page":"115653","DOI":"10.1016\/j.intimp.2025.115653","volume":"167","author":"YJ Um","year":"2025","unstructured":"Um YJ, Kwak D, Kim SY, Chang HJ, Yum SH, Hwang J, Kim JE, Jung JY, Hong SH, Park S, Lee J, Kim SK, Oh YS, Seo MD, Kim MR, Park SG (2025) Enhancing anti-tumor immunity through TIGIT blockade and tumor-directed targeting in pancreatic cancer. Int Immunopharmacol 167:115653","journal-title":"Int Immunopharmacol"},{"key":"2327_CR48","doi-asserted-by":"publisher","first-page":"e008755","DOI":"10.1136\/jitc-2023-008755","volume":"13","author":"MM Cho","year":"2025","unstructured":"Cho MM, Song L, Quamine AE, Szewc F, Shi L, Ebben JD, Turicek DP, Kline JM, Burpee DM, Lafeber EO, Phillips MF, Ceas AS, Bates PD, Forsberg MH, Kink JA, Erbe AK, Capitini CM (2025) CD155 blockade enhances allogeneic natural killer cell-mediated antitumor response against osteosarcoma. J Immunother Cancer 13:e008755","journal-title":"J Immunother Cancer"},{"key":"2327_CR49","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1002\/eji.201545480","volume":"45","author":"F Wang","year":"2015","unstructured":"Wang F, Hou H, Wu S, Tang Q, Liu W, Huang M, Yin B, Huang J, Mao L, Lu Y, Sun Z (2015) TIGIT expression levels on human NK cells correlate with functional heterogeneity among healthy individuals. Eur J Immunol 45:2886\u20132897","journal-title":"Eur J Immunol"},{"key":"2327_CR50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00262-024-03867-3","volume":"74","author":"VE Stefan","year":"2024","unstructured":"Stefan VE, Weber DD, Lang R, Kofler B (2024) Overcoming immunosuppression in cancer: how ketogenic diets boost immune checkpoint blockade. Cancer Immunol Immunother 74:23","journal-title":"Cancer Immunol Immunother"},{"key":"2327_CR51","doi-asserted-by":"publisher","first-page":"17858","DOI":"10.1073\/pnas.0903474106","volume":"106","author":"N Stanietsky","year":"2009","unstructured":"Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A, Levine Z, Beiman M, Dassa L, Achdout H, Stern-Ginossar N, Tsukerman P, Jonjic S, Mandelboim O (2009) The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A 106:17858\u201317863","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2327_CR52","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3390\/cancers11060877","volume":"11","author":"B Sanchez-Correa","year":"2019","unstructured":"Sanchez-Correa B, Valhondo I, Hassouneh F, Lopez-Sejas N, Pera A, Bergua JM, Arcos MJ, Banas H, Casas-Aviles I, Duran E, Alonso C, Solana R, Tarazona R (2019) DNAM-1 and the TIGIT\/PVRIG\/TACTILE Axis: novel immune checkpoints for natural killer cell-based cancer immunotherapy. Cancers (Basel) 11:877","journal-title":"Cancers (Basel)"},{"key":"2327_CR53","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/1535-7163.MCT-23-0614","volume":"24","author":"Y Lin","year":"2025","unstructured":"Lin Y, Lin K, Fu Q, Sun X, Wang H, Su L, Xu Y, Liao C (2025) Co-blocking TIGIT and PVRIG using a novel bispecific antibody enhances antitumor immunity. Mol Cancer Ther 24:664\u2013677","journal-title":"Mol Cancer Ther"},{"key":"2327_CR54","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/cdd.2012.141","volume":"20","author":"S Liu","year":"2013","unstructured":"Liu S, Zhang H, Li M, Hu D, Li C, Ge B, Jin B, Fan Z (2013) Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells. Cell Death Differ 20:456\u2013464","journal-title":"Cell Death Differ"},{"key":"2327_CR55","doi-asserted-by":"publisher","first-page":"17647","DOI":"10.1074\/jbc.M114.572420","volume":"289","author":"M Li","year":"2014","unstructured":"Li M, Xia P, Du Y, Liu S, Huang G, Chen J, Zhang H, Hou N, Cheng X, Zhou L, Li P, Yang X, Fan Z (2014) T-cell immunoglobulin and ITIM domain (TIGIT) receptor\/poliovirus receptor (PVR) ligand engagement suppresses interferon-gamma production of natural killer cells via beta-arrestin 2-mediated negative signaling. J Biol Chem 289:17647\u201317657","journal-title":"J Biol Chem"},{"key":"2327_CR56","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","volume":"55","author":"KL Banta","year":"2022","unstructured":"Banta KL, Xu X, Chitre AS, Au-Yeung A, Takahashi C, O\u2019Gorman WE, Wu TD, Mittman S, Cubas R, Comps-Agrar L, Fulzele A, Bennett EJ, Grogan JL, Hui E, Chiang EY, Mellman I (2022) Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8(+) T cell responses. Immunity 55:512\u2013526e519","journal-title":"Immunity"},{"key":"2327_CR57","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1093\/intimm\/dxg134","volume":"15","author":"A Verbrugge","year":"2003","unstructured":"Verbrugge A, Ruiter Td T, Clevers H, Meyaard L (2003) Differential contribution of the immunoreceptor tyrosine-based inhibitory motifs of human leukocyte-associated Ig-like receptor-1 to inhibitory function and phosphatase recruitment. Int Immunol 15:1349\u20131358","journal-title":"Int Immunol"},{"key":"2327_CR58","doi-asserted-by":"publisher","first-page":"8989","DOI":"10.1074\/jbc.272.14.8989","volume":"272","author":"M Blery","year":"1997","unstructured":"Blery M, Delon J, Trautmann A, Cambiaggi A, Olcese L, Biassoni R, Moretta L, Chavrier P, Moretta A, Daeron M, Vivier E (1997) Reconstituted killer cell inhibitory receptors for major histocompatibility complex class I molecules control mast cell activation induced via immunoreceptor tyrosine-based activation motifs. J Biol Chem 272:8989\u20138996","journal-title":"J Biol Chem"},{"key":"2327_CR59","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.4049\/jimmunol.173.3.1571","volume":"173","author":"YM Vyas","year":"2004","unstructured":"Vyas YM, Maniar H, Lyddane CE, Sadelain M, Dupont B (2004) Ligand binding to inhibitory killer cell Ig-like receptors induce colocalization with Src homology domain 2-containing protein tyrosine phosphatase 1 and interruption of ongoing activation signals. J Immunol 173:1571\u20131578","journal-title":"J Immunol"},{"key":"2327_CR60","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-020-00913-2","volume":"13","author":"KB Lupo","year":"2020","unstructured":"Lupo KB, Matosevic S (2020) CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma. J Hematol Oncol 13:76","journal-title":"J Hematol Oncol"},{"key":"2327_CR61","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","volume":"19","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, Wang Z, Wu Q, Peng H, Wei H, Sun R, Tian Z (2018) Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol 19:723\u2013732","journal-title":"Nat Immunol"},{"key":"2327_CR62","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/neuonc\/nop009","volume":"12","author":"CA Crane","year":"2010","unstructured":"Crane CA, Han SJ, Barry JJ, Ahn BJ, Lanier LL, Parsa AT (2010) TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8\u2009+\u2009T cells in glioma patients. Neuro Oncol 12:7\u201313","journal-title":"Neuro Oncol"},{"key":"2327_CR63","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.molimm.2022.04.014","volume":"147","author":"X Tian","year":"2022","unstructured":"Tian X, Ning Q, Yu J, Tang S (2022) T-cell immunoglobulin and ITIM domain in cancer immunotherapy: a focus on tumor-infiltrating regulatory T cells. Mol Immunol 147:62\u201370","journal-title":"Mol Immunol"},{"key":"2327_CR64","doi-asserted-by":"publisher","first-page":"O13","DOI":"10.1186\/2051-1426-2-S3-O13","volume":"2","author":"S Kurtulus","year":"2014","unstructured":"Kurtulus S, Sakuishi K, Zhang H, Joller N, Tan D, Smyth M, Kuchroo V, Anderson A (2014) Mechanisms of TIGIT-driven immune suppression in cancer. J Immunother Cancer 2:O13","journal-title":"J Immunother Cancer"},{"key":"2327_CR65","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1002\/cam4.2976","volume":"9","author":"F Chen","year":"2020","unstructured":"Chen F, Xu Y, Chen Y, Shan S (2020) TIGIT enhances CD4(+) regulatory T-cell response and mediates immune suppression in a murine ovarian cancer model. Cancer Med 9:3584\u20133591","journal-title":"Cancer Med"},{"key":"2327_CR66","doi-asserted-by":"publisher","first-page":"145","DOI":"10.4049\/jimmunol.1402381","volume":"195","author":"CA Fuhrman","year":"2015","unstructured":"Fuhrman CA, Yeh WI, Seay HR, Saikumar Lakshmi P, Chopra G, Zhang L, Perry DJ, McClymont SA, Yadav M, Lopez MC, Baker HV, Zhang Y, Li Y, Whitley M, von Schack D, Atkinson MA, Bluestone JA, Brusko TM (2015) Divergent phenotypes of human regulatory T cells expressing the receptors TIGIT and CD226. J Immunol 195:145\u2013155","journal-title":"J Immunol"},{"key":"2327_CR67","doi-asserted-by":"publisher","first-page":"e19215","DOI":"10.1016\/j.heliyon.2023.e19215","volume":"9","author":"R Fujie","year":"2023","unstructured":"Fujie R, Kurowarabe K, Yamada Y, Fujiwara K, Nakatani H, Tsutsumi K, Hayashi R, Kawahata H, Miyamoto M, Ozawa M, Katakai T, Takahama Y, Ohigashi I, Hayasaka H (2023) Endogenous CCL21-Ser deficiency reduces B16-F10 melanoma growth by enhanced antitumor immunity. Heliyon 9:e19215","journal-title":"Heliyon"},{"key":"2327_CR68","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00018-023-04788-7","volume":"80","author":"LH Geraldo","year":"2023","unstructured":"Geraldo LH, Garcia C, Xu Y, Leser FS, Grimaldi I, de Camargo Magalhaes ES, Dejaegher J, Solie L, Pereira CM, Correia AH, De Vleeschouwer S, Tavitian B, Canedo NHS, Mathivet T, Thomas JL, Eichmann A, Lima FRS (2023) CCL21-CCR7 signaling promotes microglia\/macrophage recruitment and chemotherapy resistance in glioblastoma. Cell Mol Life Sci 80:179","journal-title":"Cell Mol Life Sci"},{"key":"2327_CR69","doi-asserted-by":"crossref","unstructured":"Zhu DS, Piovesan D, Reiner GL, Mitchell CG, Schweickert PG, Walker NP, Walters M, Sivick Gauthier KE (2024) 507 TIGIT blockade by monoclonal antibodies promotes T cell activation and anti-tumor activity that is not dependent on a functionalized Fc domain. J Immunother Cancer 12","DOI":"10.1136\/jitc-2024-SITC2024.0507"},{"key":"2327_CR70","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.3390\/cancers16111950","volume":"16","author":"LY Wu","year":"2024","unstructured":"Wu LY, Park SH, Jakobsson H, Shackleton M, Moller A, Signalling (2024) Immune regulation and immune therapy in melanoma: review with emphasis on CD155 signalling. Cancers (Basel), 16: 1950","journal-title":"Cancers (Basel)"},{"key":"2327_CR71","doi-asserted-by":"publisher","first-page":"143557","DOI":"10.1016\/j.ijbiomac.2025.143557","volume":"310","author":"K Mortezaee","year":"2025","unstructured":"Mortezaee K (2025) T-cell immunoglobulin and ITIM domain as a target in combo anti-PD-(L)1 cancer therapy. Int J Biol Macromol 310:143557","journal-title":"Int J Biol Macromol"},{"key":"2327_CR72","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1074-7613(00)70060-4","volume":"4","author":"A Shibuya","year":"1996","unstructured":"Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, McClanahan T, Kitamura T, Nicholl J, Sutherland GR, Lanier LL, Phillips JH (1996) DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 4:573\u2013581","journal-title":"Immunity"},{"key":"2327_CR73","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S1074-7613(00)80136-3","volume":"11","author":"K Shibuya","year":"1999","unstructured":"Shibuya K, Lanier LL, Phillips JH, Ochs HD, Shimizu K, Nakayama E, Nakauchi H, Shibuya A (1999) Physical and functional association of LFA-1 with DNAM-1 adhesion molecule. Immunity 11:615\u2013623","journal-title":"Immunity"},{"key":"2327_CR74","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1084\/jem.20150792","volume":"212","author":"Z Zhang","year":"2015","unstructured":"Zhang Z, Wu N, Lu Y, Davidson D, Colonna M, Veillette A (2015) DNAM-1 controls NK cell activation via an ITT-like motif. J Exp Med 212:2165\u20132182","journal-title":"J Exp Med"},{"key":"2327_CR75","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.4049\/jimmunol.1103627","volume":"188","author":"E Lozano","year":"2012","unstructured":"Lozano E, Dominguez-Villar M, Kuchroo V, Hafler DA (2012) The TIGIT\/CD226 axis regulates human T cell function. J Immunol 188:3869\u20133875","journal-title":"J Immunol"},{"key":"2327_CR76","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","volume":"26","author":"RJ Johnston","year":"2014","unstructured":"Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, Park S, Javinal V, Chiu H, Irving B, Eaton DL, Grogan JL (2014) The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 26:923\u2013937","journal-title":"Cancer Cell"},{"key":"2327_CR77","doi-asserted-by":"publisher","first-page":"e1196308","DOI":"10.1080\/2162402X.2016.1196308","volume":"5","author":"CJ Kearney","year":"2016","unstructured":"Kearney CJ, Ramsbottom KM, Voskoboinik I, Darcy PK, Oliaro J (2016) Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing. Oncoimmunology 5:e1196308","journal-title":"Oncoimmunology"},{"key":"2327_CR78","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1158\/2326-6066.CIR-18-0022","volume":"6","author":"CF Guillamon","year":"2018","unstructured":"Guillamon CF, Martinez-Sanchez MV, Gimeno L, Mrowiec A, Martinez-Garcia J, Server-Pastor G, Martinez-Escribano J, Torroba A, Ferri B, Abellan D, Campillo JA, Legaz I, Lopez-Alvarez MR, Moya-Quiles MR, Muro M, Minguela A (2018) NK cell education in tumor immune surveillance: DNAM-1\/KIR receptor ratios as predictive biomarkers for solid tumor outcome. Cancer Immunol Res 6:1537\u20131547","journal-title":"Cancer Immunol Res"},{"key":"2327_CR79","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/j.1365-2567.2007.02660.x","volume":"122","author":"JA Belisle","year":"2007","unstructured":"Belisle JA, Gubbels JA, Raphael CA, Migneault M, Rancourt C, Connor JP, Patankar MS (2007) Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology 122:418\u2013429","journal-title":"Immunology"},{"key":"2327_CR80","doi-asserted-by":"publisher","first-page":"e22842","DOI":"10.1371\/journal.pone.0022842","volume":"6","author":"EB Wilson","year":"2011","unstructured":"Wilson EB, El-Jawhari JJ, Neilson AL, Hall GD, Melcher AA, Meade JL, Cook GP (2011) Human tumour immune evasion via TGF-beta blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. PLoS ONE 6:e22842","journal-title":"PLoS ONE"},{"key":"2327_CR81","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00262-018-2121-4","volume":"67","author":"R Fujii","year":"2018","unstructured":"Fujii R, Jochems C, Tritsch SR, Wong HC, Schlom J, Hodge JW (2018) An IL-15 superagonist\/IL-15Ralpha fusion complex protects and rescues NK cell-cytotoxic function from TGF-beta1-mediated immunosuppression. Cancer Immunol Immunother 67:675\u2013689","journal-title":"Cancer Immunol Immunother"},{"key":"2327_CR82","doi-asserted-by":"publisher","first-page":"15177","DOI":"10.3390\/ijms232315177","volume":"23","author":"T Huyan","year":"2022","unstructured":"Huyan T, Gao L, Gao N, Wang C, Guo W, Zhou X, Li Q (2022) miR-221-5p and miR-186-5p are the critical bladder cancer derived exosomal miRNAs in natural killer cell dysfunction. Int J Mol Sci 23:15177","journal-title":"Int J Mol Sci"},{"key":"2327_CR83","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1084\/jem.20081752","volume":"205","author":"S Gilfillan","year":"2008","unstructured":"Gilfillan S, Chan CJ, Cella M, Haynes NM, Rapaport AS, Boles KS, Andrews DM, Smyth MJ, Colonna M (2008) DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med 205:2965\u20132973","journal-title":"J Exp Med"},{"key":"2327_CR84","doi-asserted-by":"publisher","first-page":"e52176","DOI":"10.7554\/eLife.52176","volume":"9","author":"AR Van Pombo Antunes","year":"2020","unstructured":"Pombo Antunes AR, Scheyltjens I, Duerinck J, Neyns B, Movahedi K, Van Ginderachter JA (2020) Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies. Elife 9:e52176","journal-title":"Elife"},{"key":"2327_CR85","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.clim.2017.08.021","volume":"190","author":"M Wang","year":"2018","unstructured":"Wang M, Bu J, Zhou M, Sido J, Lin Y, Liu G, Lin Q, Xu X, Leavenworth JW, Shen E (2018) CD8(+)T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients. Clin Immunol 190:64\u201373","journal-title":"Clin Immunol"},{"key":"2327_CR86","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/imr.12518","volume":"276","author":"WC Dougall","year":"2017","unstructured":"Dougall WC, Kurtulus S, Smyth MJ, Anderson AC (2017) TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunol Rev 276:112\u2013120","journal-title":"Immunol Rev"},{"key":"2327_CR87","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1158\/1078-0432.CCR-16-0933","volume":"22","author":"SJ Blake","year":"2016","unstructured":"Blake SJ, Dougall WC, Miles JJ, Teng MW, Smyth MJ (2016) Molecular pathways: targeting CD96 and TIGIT for cancer immunotherapy. Clin Cancer Res 22:5183\u20135188","journal-title":"Clin Cancer Res"},{"key":"2327_CR88","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.3389\/fimmu.2018.01072","volume":"9","author":"H Georgiev","year":"2018","unstructured":"Georgiev H, Ravens I, Papadogianni G, Bernhardt G (2018) Coming of age: CD96 emerges as modulator of immune responses. Front Immunol 9:1072","journal-title":"Front Immunol"},{"key":"2327_CR89","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.4049\/jimmunol.172.7.3994","volume":"172","author":"A Fuchs","year":"2004","unstructured":"Fuchs A, Cella M, Giurisato E, Shaw AS, Colonna M (2004) Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155). J Immunol 172:3994\u20133998","journal-title":"J Immunol"},{"key":"2327_CR90","doi-asserted-by":"publisher","first-page":"592","DOI":"10.3389\/fbioe.2020.00592","volume":"8","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Zhong H, Fan Y, Liu Q, Song J, Yao S, Cao F (2020) Immune and clinical features of CD96 expression in glioma by in silico analysis. Front Bioeng Biotechnol 8:592","journal-title":"Front Bioeng Biotechnol"},{"key":"2327_CR91","doi-asserted-by":"publisher","first-page":"10768","DOI":"10.1038\/s41598-020-66806-z","volume":"10","author":"F Liu","year":"2020","unstructured":"Liu F, Huang J, He F, Ma X, Fan F, Meng M, Zhuo Y, Zhang L (2020) CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma. Sci Rep 10:10768","journal-title":"Sci Rep"},{"key":"2327_CR92","doi-asserted-by":"publisher","first-page":"634617","DOI":"10.3389\/fonc.2021.634617","volume":"11","author":"W Ye","year":"2021","unstructured":"Ye W, Luo C, Liu F, Liu Z, Chen F (2021) CD96 correlates with immune infiltration and impacts patient prognosis: a pan-cancer analysis. Front Oncol 11:634617","journal-title":"Front Oncol"},{"key":"2327_CR93","doi-asserted-by":"publisher","first-page":"e2202956","DOI":"10.1002\/advs.202202956","volume":"10","author":"J Li","year":"2023","unstructured":"Li J, Xia Q, Di C, Li C, Si H, Zhou B, Yu S, Li Y, Huang J, Lu Y, Huang M, Liang H, Liu X, Zhao Q (2023) Tumor cell-intrinsic CD96 mediates chemoresistance and cancer stemness by regulating mitochondrial fatty acid beta-oxidation. Adv Sci (Weinh) 10:e2202956","journal-title":"Adv Sci (Weinh)"},{"key":"2327_CR94","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/ni.2850","volume":"15","author":"CJ Chan","year":"2014","unstructured":"Chan CJ, Martinet L, Gilfillan S, Souza-Fonseca-Guimaraes F, Chow MT, Town L, Ritchie DS, Colonna M, Andrews DM, Smyth MJ (2014) The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol 15:431\u2013438","journal-title":"Nat Immunol"},{"key":"2327_CR95","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/intimm\/dxh059","volume":"CD112","author":"S Tahara-Hanaoka","year":"2004","unstructured":"Tahara-Hanaoka S, Shibuya K, Onoda Y, Zhang H, Yamazaki S, Miyamoto A, Honda S, Lanier LL, Shibuya A (2004) Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2\/. Int Immunol CD112:533\u2013538","journal-title":"Int Immunol"},{"key":"2327_CR96","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1158\/2326-6066.CIR-18-0637","volume":"7","author":"D Mittal","year":"2019","unstructured":"Mittal D, Lepletier A, Madore J, Aguilera AR, Stannard K, Blake SJ, Whitehall VLJ, Liu C, Bettington ML, Takeda K, Long GV, Scolyer RA, Lan R, Siemers N, Korman A, Teng MWL, Johnston RJ, Dougall WC, Smyth MJ (2019) CD96 Is an immune checkpoint that regulates CD8(+) T-cell antitumor function. Cancer Immunol Res 7:559\u2013571","journal-title":"Cancer Immunol Res"},{"key":"2327_CR97","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41392-021-00730-0","volume":"6","author":"M Feng","year":"2021","unstructured":"Feng M, Wu Z, Zhou Y, Wei Z, Tian E, Mei S, Zhu Y, Liu C, He F, Li H, Xie C, Jin J, Dong J, Yang D, Yu K, Qian J, Lambrechts D, Wang MW, Zhu D (2021) BCL9 regulates CD226 and CD96 checkpoints in CD8(+) T cells to improve PD-1 response in cancer. Signal Transduct Target Ther 6:313","journal-title":"Signal Transduct Target Ther"},{"key":"2327_CR98","doi-asserted-by":"publisher","first-page":"e003667","DOI":"10.1136\/jitc-2021-003667","volume":"10","author":"Y Wang","year":"2022","unstructured":"Wang Y, Wang C, Qiu J, Qu X, Peng J, Lu C, Zhang M, Zhang M, Qi X, Li G, Hua K (2022) Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8\u2009+\u2009TIL function in cervical cancer. J Immunother Cancer 10:e003667","journal-title":"J Immunother Cancer"},{"key":"2327_CR99","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1038\/s41423-020-00538-y","volume":"18","author":"H Zhang","year":"2021","unstructured":"Zhang H, Liu Q, Lei Y, Zhou J, Jiang W, Cui Y, He Q, Zhu J, Zhu Z, Sun Y, Ke Z (2021) Direct interaction between CD155 and CD96 promotes immunosuppression in lung adenocarcinoma. Cell Mol Immunol 18:1575\u20131577","journal-title":"Cell Mol Immunol"},{"key":"2327_CR100","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/eji.201948405","volume":"50","author":"EY Chiang","year":"2020","unstructured":"Chiang EY, de Almeida PE, de Almeida Nagata DE, Bowles KH, Du X, Chitre AS, Banta KL, Kwon Y, McKenzie B, Mittman S, Cubas R, Anderson KR, Warming S, Grogan JL (2020) CD96 functions as a co-stimulatory receptor to enhance CD8(+) T cell activation and effector responses. Eur J Immunol 50:891\u2013902","journal-title":"Eur J Immunol"},{"key":"2327_CR101","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.it.2016.10.002","volume":"38","author":"NA Manieri","year":"2017","unstructured":"Manieri NA, Chiang EY, Grogan JL (2017) TIGIT: a key inhibitor of the cancer immunity cycle. Trends Immunol 38:20\u201328","journal-title":"Trends Immunol"},{"key":"2327_CR102","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1093\/neuonc\/noad052","volume":"25","author":"Y Yang","year":"2023","unstructured":"Yang Y, Brown MC, Zhang G, Stevenson K, Mohme M, Kornahrens R, Bigner DD, Ashley DM, Lopez GY, Gromeier M (2023) Polio virotherapy targets the malignant glioma myeloid infiltrate with diffuse microglia activation engulfing the CNS. Neuro Oncol 25:1631\u20131643","journal-title":"Neuro Oncol"},{"key":"2327_CR103","doi-asserted-by":"publisher","first-page":"e0085422","DOI":"10.1128\/mbio.00854-22","volume":"13","author":"MI Dobrikov","year":"2022","unstructured":"Dobrikov MI, Dobrikova EY, McKay ZP, Kastan JP, Brown MC, Gromeier M (2022) PKR Binds enterovirus IRESs, displaces host translation factors, and impairs viral translation to enable innate antiviral signaling. mBio 13:e0085422","journal-title":"mBio"},{"key":"2327_CR104","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJMoa1716435","volume":"379","author":"A Desjardins","year":"2018","unstructured":"Desjardins A, Gromeier M, Herndon JE 2nd, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD (2018) Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med 379:150\u2013161","journal-title":"N Engl J Med"},{"key":"2327_CR105","doi-asserted-by":"publisher","first-page":"e002203","DOI":"10.1136\/jitc-2020-002203","volume":"9","author":"GM Beasley","year":"2021","unstructured":"Beasley GM, Nair SK, Farrow NE, Landa K, Selim MA, Wiggs CA, Jung SH, Bigner DD, True Kelly A, Gromeier M, Salama AK (2021) Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma. J Immunother Cancer 9:e002203","journal-title":"J Immunother Cancer"},{"key":"2327_CR106","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.annonc.2021.03.197","volume":"32","author":"AB Carpenter","year":"2021","unstructured":"Carpenter AB, Carpenter AM, Aiken R, Hanft S (2021) Oncolytic virus in gliomas: a review of human clinical investigations. Ann Oncol 32:968\u2013982","journal-title":"Ann Oncol"},{"key":"2327_CR107","doi-asserted-by":"publisher","first-page":"108193","DOI":"10.1016\/j.pharmthera.2022.108193","volume":"239","author":"G Ghajar-Rahimi","year":"2022","unstructured":"Ghajar-Rahimi G, Kang KD, Totsch SK, Gary S, Rocco A, Blitz S, Kachurak K, Chambers MR, Li R, Beierle EA, Bag A, Johnston JM, Markert JM, Bernstock JD, Friedman GK (2022) Clinical advances in oncolytic virotherapy for pediatric brain tumors. Pharmacol Ther 239:108193","journal-title":"Pharmacol Ther"},{"key":"2327_CR108","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1126\/scitranslmed.aan4220","volume":"9","author":"MC Brown","year":"2017","unstructured":"Brown MC, Holl EK, Boczkowski D, Dobrikova E, Mosaheb M, Chandramohan V, Bigner DD, Gromeier M, Nair SK (2017) Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. Sci Transl Med 9:eaan4220","journal-title":"Sci Transl Med"},{"key":"2327_CR109","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/jnen\/nly045","volume":"77","author":"EM Thompson","year":"2018","unstructured":"Thompson EM, Brown M, Dobrikova E, Ramaswamy V, Taylor MD, McLendon R, Sanks J, Chandramohan V, Bigner D, Gromeier M (2018) Poliovirus receptor (CD155) expression in pediatric brain tumors mediates oncolysis of medulloblastoma and pleomorphic xanthoastrocytoma. J Neuropathol Exp Neurol 77:696\u2013702","journal-title":"J Neuropathol Exp Neurol"},{"key":"2327_CR110","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nrd.2016.178","volume":"15","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, Kohlhapp FJ, Zloza A (2016) Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 15:660","journal-title":"Nat Rev Drug Discov"},{"key":"2327_CR111","doi-asserted-by":"publisher","first-page":"922","DOI":"10.3390\/ijms21030922","volume":"21","author":"R Molfetta","year":"2020","unstructured":"Molfetta R, Zitti B, Lecce M, Milito ND, Stabile H, Fionda C, Cippitelli M, Gismondi A, Santoni A, Paolini R (2020) CD155: A multi-functional molecule in tumor progression. Int J Mol Sci 21:922","journal-title":"Int J Mol Sci"},{"key":"2327_CR112","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1007\/s10637-018-0683-9","volume":"37","author":"H Zhao","year":"2019","unstructured":"Zhao H, Ma J, Lei T, Ma W, Zhang M (2019) The bispecific anti-CD3 x anti-CD155 antibody mediates T cell immunotherapy for human prostate cancer. Invest New Drugs 37:810\u2013817","journal-title":"Invest New Drugs"},{"key":"2327_CR113","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/13880209.2020.1865410","volume":"59","author":"W Ng","year":"2021","unstructured":"Ng W, Gong C, Yan X, Si G, Fang C, Wang L, Zhu X, Xu Z, Yao C, Zhu S (2021) Targeting CD155 by rediocide-A overcomes tumour immuno-resistance to natural killer cells. Pharm Biol 59:47\u201353","journal-title":"Pharm Biol"},{"key":"2327_CR114","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.bbrc.2017.06.037","volume":"490","author":"Y Meng","year":"2017","unstructured":"Meng Y, Zhao Z, Zhu W, Yang T, Deng X, Bao R (2017) CD155 blockade improves survival in experimental sepsis by reversing dendritic cell dysfunction. Biochem Biophys Res Commun 490:283\u2013289","journal-title":"Biochem Biophys Res Commun"},{"key":"2327_CR115","doi-asserted-by":"publisher","first-page":"6441","DOI":"10.1002\/jcp.26435","volume":"233","author":"H Nasiri","year":"2018","unstructured":"Nasiri H, Valedkarimi Z, Aghebati-Maleki L, Majidi J (2018) Antibody-drug conjugates: promising and efficient tools for targeted cancer therapy. J Cell Physiol 233:6441\u20136457","journal-title":"J Cell Physiol"},{"key":"2327_CR116","doi-asserted-by":"publisher","first-page":"236","DOI":"10.2174\/1574884712666180802095521","volume":"13","author":"M Hasan","year":"2018","unstructured":"Hasan M, Alam S, Poddar SK (2018) Antibody-drug conjugates: a review on the epitome of targeted anti- cancer therapy. Curr Clin Pharmacol 13:236\u2013251","journal-title":"Curr Clin Pharmacol"},{"key":"2327_CR117","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Duran I, Lee JL, Matsubara N, Vulsteke C, Castellano D, Wu C, Campbell M, Matsangou M, Petrylak DP (2021) Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 384:1125\u20131135","journal-title":"N Engl J Med"},{"key":"2327_CR118","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s13046-021-02068-5","volume":"40","author":"B Wu","year":"2021","unstructured":"Wu B, Zhong C, Lang Q, Liang Z, Zhang Y, Zhao X, Yu Y, Zhang H, Xu F, Tian Y (2021) Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy. J Exp Clin Cancer Res 40:267","journal-title":"J Exp Clin Cancer Res"},{"key":"2327_CR119","first-page":"1825","volume":"8","author":"LD Uppendahl","year":"2017","unstructured":"Uppendahl LD, Dahl CM, Miller JS, Felices M, Geller MA (2017) Nat killer cell-based immunotherapy gynecologic malignancy: Rev Front Immunol 8:1825","journal-title":"Nat Killer Cell-Based Immunotherapy Gynecologic Malignancy: Rev Front Immunol"},{"key":"2327_CR120","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/GCO.0000000000000518","volume":"31","author":"B Schaar","year":"2019","unstructured":"Schaar B, Krishnan V, Tallapragada S, Chanana A, Dorigo O (2019) Cell-based immunotherapy in gynecologic malignancies. Curr Opin Obstet Gynecol 31:43\u201348","journal-title":"Curr Opin Obstet Gynecol"},{"key":"2327_CR121","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.7150\/ijbs.88539","volume":"20","author":"J Li","year":"2024","unstructured":"Li J, Hu H, Lian H, Yang S, Liu M, He J, Cao B, Chen D, Hu Y, Zhi C, Shen Y, Ye X, He B, Zhao M, Fan W, Xu L, Leidner R, Wu Q, Yang L, Zhang Z (2024) NK-92MI cells engineered with anti-claudin-6 chimeric antigen receptors in immunotherapy for ovarian cancer. Int J Biol Sci 20:1578\u20131601","journal-title":"Int J Biol Sci"},{"key":"2327_CR122","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers JA, Miller JS (2021) Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol 18:85\u2013100","journal-title":"Nat Rev Clin Oncol"},{"key":"2327_CR123","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1002\/eji.201243072","volume":"43","author":"N Stanietsky","year":"2013","unstructured":"Stanietsky N, Rovis TL, Glasner A, Seidel E, Tsukerman P, Yamin R, Enk J, Jonjic S, Mandelboim O (2013) Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR. Eur J Immunol 43:2138\u20132150","journal-title":"Eur J Immunol"},{"key":"2327_CR124","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1158\/2159-8290.CD-15-0944","volume":"6","author":"SJ Blake","year":"2016","unstructured":"Blake SJ, Stannard K, Liu J, Allen S, Yong MC, Mittal D, Aguilera AR, Miles JJ, Lutzky VP, de Andrade LF, Martinet L, Colonna M, Takeda K, Kuhnel F, Gurlevik E, Bernhardt G, Teng MW, Smyth MJ (2016) Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy. Cancer Discov 6:446\u2013459","journal-title":"Cancer Discov"},{"key":"2327_CR125","doi-asserted-by":"publisher","first-page":"e1424677","DOI":"10.1080\/2162402X.2018.1424677","volume":"7","author":"A Roman Aguilera","year":"2018","unstructured":"Roman Aguilera A, Lutzky VP, Mittal D, Li XY, Stannard K, Takeda K, Bernhardt G, Teng MWL, Dougall WC, Smyth MJ (2018) CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity. Oncoimmunology 7:e1424677","journal-title":"Oncoimmunology"},{"key":"2327_CR126","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.coi.2018.03.014","volume":"51","author":"A Kunert","year":"2018","unstructured":"Kunert A, Debets R (2018) Engineering T cells for adoptive therapy: outsmarting the tumor. Curr Opin Immunol 51:133\u2013139","journal-title":"Curr Opin Immunol"},{"key":"2327_CR127","doi-asserted-by":"publisher","first-page":"618387","DOI":"10.3389\/fimmu.2020.618387","volume":"11","author":"L Lindo","year":"2020","unstructured":"Lindo L, Wilkinson LH, Hay KA (2020) Befriending the hostile tumor microenvironment in CAR T-cell therapy. Front Immunol 11:618387","journal-title":"Front Immunol"},{"key":"2327_CR128","doi-asserted-by":"publisher","first-page":"11781","DOI":"10.3390\/ijms222111781","volume":"22","author":"C de la Aparicio","year":"2021","unstructured":"Aparicio C, Belver M, Enriquez L, Espeso F, Nunez L, Sanchez A, de la Fuente MA, Gonzalez-Vallinas M (2021) Cell therapy for colorectal cancer: the promise of chimeric antigen receptor (CAR)-T cells. Int J Mol Sci 22:11781","journal-title":"Int J Mol Sci"},{"key":"2327_CR129","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12943-018-0840-y","volume":"17","author":"Y Pang","year":"2018","unstructured":"Pang Y, Hou X, Yang C, Liu Y, Jiang G (2018) Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy. Mol Cancer 17:91","journal-title":"Mol Cancer"},{"key":"2327_CR130","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s11095-018-2436-z","volume":"35","author":"P Salmikangas","year":"2018","unstructured":"Salmikangas P, Kinsella N, Chamberlain P (2018) Chimeric antigen receptor T-cells (CAR T-Cells) for cancer immunotherapy\u2014Moving target for industry? Pharm Res 35:152","journal-title":"Pharm Res"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-026-02327-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-026-02327-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-026-02327-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:03:52Z","timestamp":1784678632000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40478-026-02327-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":130,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2327"],"URL":"https:\/\/doi.org\/10.1186\/s40478-026-02327-6","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"13 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"154"}}